Phase I Trial of Bortezomib in Combination with Rituximab-HyperCVAD/Methotrexate and Cytarabine for Untreated Mantle Cell Lymphoma

被引：0
|
作者：
Romaguera, Jorge [1 ]
Fayad, Luis [1 ]
McLaughlin, Peter [1 ]
Pro, Barbara [1 ]
Rodriguez, Maria Alma [1 ]
Wang, Michael [1 ]
Weaver, Pamela [1 ]
Hartig, Kimberly [1 ]
Kwak, Larry [1 ]
Feldman, Tatyana [2 ]
Smith, Judy [2 ]
Ford, Peggy [2 ]
Goldberg, Stuart [2 ]
Pecora, Andrew [2 ]
Goy, Andre [2 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Div Canc Med, Houston, TX 77030 USA
[2] Hackensack Univ, Med Ctr, Dept Lymphoma, Hackensack, NJ USA
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1049 / 1049
页数：1
相关论文
共 50 条
  • [21] Rituximab (R) plus Hypercvad Alternating with R-Methotrexate/Cytarabine after 9 Years: Continued High Rate of Failure-Free Survival in Untreated Mantle Cell Lymphoma (MCL)
    Romaguera, Jorge
    Fayad, Luis
    Rodriguez, Alma
    Hagemeister, Fb
    Pro, Barbara
    McLaughlin, Peter
    Younes, Anas
    Samaniego, Felipe
    Shah, Jatin
    Weaver, Pamela
    Hartig, Kim
    Cabanillas, Fernando
    Kwak, Larry
    Kantarjian, Hagop
    Wang, Michael
    BLOOD, 2008, 112 (11) : 309 - 309
  • [22] Phase 2 Trial of Rituximab Plus Hyper-CVAD Alternating With Rituximab Plus Methotrexate-Cytarabine for Relapsed or Refractory Aggressive Mantle Cell Lymphoma
    Wang, Michael
    Fayad, Luis
    Cabanillas, Fernando
    Hagerneister, Fredrick
    McLaughlin, Peter
    Rodriguez, Maria A.
    Kwak, Larry W.
    Zhou, Yuhong
    Kantarjian, Hagop
    Romaguera, Jorge
    CANCER, 2008, 113 (10) : 2734 - 2741
  • [23] Combination of Ibrutinib with Rituximab (IR) in Previously Untreated Older Patients with Mantle Cell Lymphoma (MCL) - a Phase II Clinical Trial
    Jain, Preetesh
    Yao, Yixin
    Zhao, Shuangtao
    Liu, Yang
    Hill, Holly
    Che, Yuxuan
    Li, Yijing
    Jordan, Alexa A.
    McIntosh, Joseph
    Lee, Hun Ju
    Steiner, Raphael Eric
    Samaniego, Felipe
    Westin, Jason
    Nastoupil, Loretta J.
    Nair, Ranjit
    Ahmed, Sairah
    Ok, Chi Young
    Kanagal-Shamanna, Rashmi
    Oriabure, Onyeka
    Xu, Guofang
    Chen, Wendy
    Moghrabi, Omar
    McClain, Chloe Marie
    Badillo, Maria
    Thirumurthi, Selvi
    Santos, David
    Iliescu, Cezar
    Yin, C. Cameron
    Li, Shaoying
    Tang, Guilin
    Vega, Francisco
    Neelapu, Sattva S.
    Flowers, Christopher
    Wang, Linghua
    Wang, Michael
    BLOOD, 2020, 136
  • [24] A phase I trial of palbociclib plus bortezomib in previously treated mantle cell lymphoma
    Martin, Peter
    Ruan, Jia
    Furman, Richard
    Rutherford, Sarah
    Allan, John
    Chen, Zhengming
    Huang, Xiangao
    DiLiberto, Maurizio
    Chen-Kiang, Selina
    Leonard, John P.
    LEUKEMIA & LYMPHOMA, 2019, 60 (12) : 2917 - 2921
  • [25] Vorinostat (SAHA), Cladribine, and Rituximab in Previously Untreated Mantle Cell Lymphoma: Updated Results From a Phase I/II Trial
    Spurgeon, Stephen E.
    Sharma, Kamal
    Claxton, David F.
    Ehmann, Christopher W.
    Gallagher, Carla
    Shimko, Sara
    Stewart, August
    Parekh, Samir
    Leshchenko, Violetta V.
    Chen, Yiyi
    Epner, Elliot M.
    BLOOD, 2012, 120 (21)
  • [26] Phase I/II trial of lenalidomide, methotrexate, leucovorin, cytarabine, and rituximab (LeMLAR) in relapsed or refractory diffuse large B cell lymphoma
    Ulrich Dührsen
    Mareike Tometten
    Frank Kroschinsky
    Arnold Ganser
    Stefan Ibach
    Stefanie Bertram
    Andreas Hüttmann
    Blood Cancer Journal, 11
  • [27] Phase I/II trial of lenalidomide, methotrexate, leucovorin, cytarabine, and rituximab (LeMLAR) in relapsed or refractory diffuse large B cell lymphoma
    Duehrsen, Ulrich
    Tometten, Mareike
    Kroschinsky, Frank
    Ganser, Arnold
    Ibach, Stefan
    Bertram, Stefanie
    Huettmann, Andreas
    BLOOD CANCER JOURNAL, 2021, 11 (05)
  • [28] The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma-a randomized, open-label phase III trial of the European mantle cell lymphoma network
    Fischer, Luca
    Jiang, Linmiao
    Duerig, Jan
    Schmidt, Christian
    Stilgenbauer, Stephan
    Bouabdallah, Krimo
    Solal-Celigny, Philippe
    Scholz, Christian W.
    Feugier, Pierre
    de Wit, Maike
    Trappe, Ralf Ulrich
    Hallek, Michael
    Graeven, Ullrich
    Haenel, Mathias
    Hoffmann, Martin
    Delwail, Vincent
    Macro, Margaret
    Greiner, Jochen
    Giagounidis, Aristoteles A. N.
    Dargel, Beate
    Durot, Eric
    Foussard, Charles
    Silkenstedt, Elisabeth
    Weigert, Oliver
    Pott, Christiane
    Klapper, Wolfram
    Hiddemann, Wolfgang
    Unterhalt, Michael
    Hoster, Eva
    Ribrag, Vincent
    Dreyling, Martin
    LEUKEMIA, 2024, 38 (06) : 1307 - 1314
  • [29] A Pilot Study of Acalabrutinib with Bendamustine/Rituximab Followed By Cytarabine/Rituximab (R-ABC) for Untreated Mantle Cell Lymphoma
    Guy, Daniel
    Watkins, Marcus
    Wan, Fei
    Bartlett, Nancy L.
    Cashen, Amanda F.
    Fehniger, Todd A.
    Ghobadi, Armin
    Mehta-Shah, Neha
    Kahl, Brad S.
    BLOOD, 2020, 136
  • [30] Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenstrom Macroglobulinemia
    Ghobrial, Irene M.
    Xie, Wanling
    Padmanabhan, Swaminathan
    Badros, Ashraf
    Rourke, Meghan
    Leduc, Renee
    Chuma, Stacey
    Kunsman, Janet
    Warren, Diane
    Poon, Tiffany
    Harris, Brianna
    Sam, Amy
    Anderson, Kenneth C.
    Richardson, Paul G.
    Treon, Steven P.
    Weller, Die
    Matous, Jeffrey
    AMERICAN JOURNAL OF HEMATOLOGY, 2010, 85 (09) : 670 - 674
12345